<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2627">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03894254</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0613</org_study_id>
    <nct_id>NCT03894254</nct_id>
  </id_info>
  <brief_title>Predictive Factors of Autonomy Loss in Real-life Cohort</brief_title>
  <acronym>MEM-AURA</acronym>
  <official_title>Predictive Factors Associated With Impairment in Functional Autonomy in a Regional Real-life Cohort of Patients With Alzheimer's Disease or Related Disorders (ADRD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Alzheimer's disease or related disorders (ADRD) are among the most disabling diseases&#xD;
      because of their main features such as cognitive impairment, loss of functional autonomy and&#xD;
      behavioural disorders. In absence of current curative treatment, the identification of the&#xD;
      predictive risk factors of progression of the disease, evaluated through its main symptoms,&#xD;
      represents a major stake of public health. The Investigators aim at developing a regional&#xD;
      database, which includes the patient medical records on a prospective basis, in collaboration&#xD;
      with the medical and administrative staff and with the University hospital computer science&#xD;
      departments.&#xD;
&#xD;
      The main objective is to study the predictive factors associated with change in functional&#xD;
      autonomy level, measured every 6 to 12 months in centres across Region Auvergne Rhone-Alpes&#xD;
      in France.&#xD;
&#xD;
      The real-life study population will consist in about 5400 patients with ADRD. The inclusion&#xD;
      period will be of 3 years, the length of follow-up of each patient will be of 10 years max&#xD;
      for a total study length of 13 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2032</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional autonomy level</measure>
    <time_frame>from 6 months to 12 months interval</time_frame>
    <description>The Lawton Instrumental Activities of Daily Living (IADL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional autonomy level</measure>
    <time_frame>from 6 months to 12 months interval</time_frame>
    <description>The Disability Assessment of Dementia (DAD-6)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional autonomy level</measure>
    <time_frame>from 6 months to 12 months interval</time_frame>
    <description>The New-AGGIR (French national score for dependency assessment)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5400</enrollment>
  <condition>Memory Disorders</condition>
  <arm_group>
    <arm_group_label>Patients with subjective cognitive complaint or neurocognitive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>: Real-life cohort patients with subjective cognitive complaint or neurocognitive disorders undergoing medical examination in memory centers, and for whom extensive evaluations will be performed for the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>This is study carried out in current practice. Patients are undergoing a medical examination in a memory center, with extensive and systematic evaluations for the study involving the following tests: IADL, DAD6, New AGGIR, NPI, and mini-Zarit) assessing the functions (autonomy, behavior and caregiver burden).</description>
    <arm_group_label>Patients with subjective cognitive complaint or neurocognitive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years and older, undergoing a medical visit in a memory center or&#xD;
             neuro-cognition service&#xD;
&#xD;
          -  Patients living at home or in housing&#xD;
&#xD;
          -  Patients with memory impairment, at all stage of the disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients in institution&#xD;
&#xD;
          -  Patients under legal protection&#xD;
&#xD;
          -  Patients with a hearing or visual impairment, which prevents carrying out examinations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Krolak-Salmon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Mémoire de Ressources et de Recherche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Krolak-Salmon, PhD</last_name>
    <phone>04 72 43 20 50</phone>
    <email>pierre.krolak-salmon@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Dugoujon</name>
      <address>
        <city>Caluire-et-Cuire</city>
        <zip>69300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Gaujard, MD</last_name>
      <phone>04 72 00 15 32</phone>
      <phone_ext>+33</phone_ext>
      <email>sylvain.gaujard@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bonnefoy, PhD</last_name>
      <phone>04 78 86 15 81</phone>
      <email>marc.bonnefoy@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de neuro-cognition et neuro-ophtalmologie du Groupement Hospitalier Est</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Desestret, PhD</last_name>
      <email>virginie.desestret@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude Getenet, MD</last_name>
      <phone>04 77 12 78 05</phone>
      <email>j.claude.getenet@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Mémoire de Ressources et de Recherche de Lyon</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Krolak-Salmon, PhD</last_name>
      <phone>04 72 43 20 50</phone>
      <email>pierre.krolak-salmon@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>April 25, 2022</last_update_submitted>
  <last_update_submitted_qc>April 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

